与SARBORG合作的管道制药团队使用人工智能进行药物开发,使库存增加23.90%。 Conduit Pharmaceuticals teams with SARBORG to use AI in drug development, boosting stock by 23.90%.

康达制药与SARBORG有限公司合作, 将AI和网络学纳入药物开发过程. Conduit Pharmaceuticals has partnered with SARBORG Limited to integrate AI and cybernetics into their drug development processes. 这种合作旨在降低成本,尽量减少人为错误,并提高药物再利用、发现和临床试验的效率。 This collaboration aims to reduce costs, minimize human error, and increase efficiency in drug repurposing, discovery, and clinical trials. 这项合作预计将于2024年12月启动,并且已经使Conduit的股价在纳斯达克上上了23.90%,达到0.11美元. The partnership is expected to launch in December 2024 and has already boosted Conduit's stock by 23.90% to $0.11 on the Nasdaq.